<DOC>
	<DOCNO>NCT02292979</DOCNO>
	<brief_summary>This study aim evaluate efficacy brentuximab vedotin + AVD combination ( doxorubicine , vinblastine , dacarbazine ) patient Hodgkin lymphoma stage I / II unfavorable diagnosis , assess negativity PET ( positron emission tomography ) two cycle chemotherapy .</brief_summary>
	<brief_title>Brentuximab Vedotin Associated With Chemotherapy Untreated Patients With Hodgkin Lymphoma .</brief_title>
	<detailed_description>Patients receive either ABVD chemotherapy ( standard treatment = doxorubicin , bleomycin , vinblastine , dacarbazine ) Brentuximab vedotin combination chemotherapy AVD ( study treatment ) , depend randomization . Radiotherapy plan chemotherapy immunochemotherapy . PET scan perform inclusion , 2 cycle chemotherapy 4 cycle chemotherapy ( PET two cycle positive ) , end treatment follow-up period .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm CD30+ classical Hodgkin lymphoma Supradiaphragmatic Ann Arbor clinical stage I II Previously untreated PET scan without IV contrast diagnosis available central review least one hypermetabolic lesion Unfavourable ( U ) characteristic accord classic EORTC/LYSA clinical prognostic factor , include patient least one follow factor : CSII ≥ 4 nodal area age ≥ 50 yr M/T ratio ≥ 0.35 ESR ≥ 50 ( without Bsymptoms ) ESR ≥ 30 Bsymptoms ECOG performance status 02 Life expectancy &gt; 6 month Age 18 60 year Availability periodic blood sampling , studyrelated assessment , management toxicity treat institution . Female patient : Are postmenopausal least 1 year screen visit , OR surgically sterile , OR If childbearing potential , agree practice 2 effective method contraception , time , 6 month last dose study drug , OR agree completely abstain heterosexual intercourse Male patient , even surgically sterilize ( ie , status postvasectomy ) , : Agree practice effective barrier contraception entire study treatment period 6 month last dose study drug , agree completely abstain heterosexual intercourse . Written informed consent . Required baseline laboratory data : Absolute neutrophil count ≥ 1,500/µL Platelet count ≥ 75,000/ µL Hemoglobin ≥ 8g/dL Serum total bilirubin ≤ 1.5 X ULN unless elevation know due Gilbert syndrome . Serum creatinine ≤ 2.0 mg/dL and/or calculate creatinine clearance &gt; 40 mL/minute ( CockcroftGault formula MDRD ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 3 X ULN Histological diagnosis different classical Hodgkin Lymphoma . Nodular lymphocyte predominant subtypes ( nodular paragranuloma Poppema paragranuloma ) exclude . Known cerebral meningeal disease etiology , include sign symptom PML Any sensory motor peripheral neuropathy ≥ Grade 2 Known history follow cardiovascular condition Myocardial infarction within 2 year randomization New York Heart Association ( NYHA ) Class III IV heart failure ( see Appendix 14 ) Evidence current uncontrolled cardiovascular condition , include cardiac arrhythmia , congestive heart failure ( CHF ) , angina , electrocardiographic evidence acute ischemia active conduction system abnormalities Recent evidence ( within 30 day first dose study drug ) leftventricular ejection fraction &lt; 50 % Unstable diabetes mellitus ( avoid uninterpretable FDGPET scan ) . Known HIV positive HCV positive HBV positive . This mean : HBsAg positive HBsAg negative , antiHBs positive and/or antiHBc positive detectable viral DNA ( HBsAg negative patient viral DNA negative patient seropositive due history hepatitis B vaccine eligible ) . Any history cancer last 5 year , exception nonmelanoma skin tumor . Carcinoma situ type exclude complete resection . Dementia alter mental status Pregnancy breastfeeding . Previous treatment antiCD30 antibody . Known hypersensitivity excipients contain BV formulation know contraindication drug contain chemotherapy regimens Treatment corticosteroid baseline PET scan Known active viral , bacterial , fungal infection require treatment antimicrobial therapy untreated know active Grade 3 viral , bacterial , fungal infection , within 2 week prior first dose BV Treatment investigational drug within 30 day first cycle treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HL</keyword>
</DOC>